|
|
||||||||
Eur J Cardiothorac Surg 1998;13:293-297
© 1998 Elsevier Science NL
a Clinic for Cardio-vascular Surgery, University Hospital, Rämistrasse 100, CH-8091 Zurich, Switzerland
b Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Womens Hospital, Harvard Medical School, Boston, MA, USA
Received 29 September 1997; received in revised form 3 December 1997; accepted 9 December 1997.
Corresponding author. Tel.: +41 1 2551111; fax: +41 1 2554369; e-mail: zund@chi.usz.ch
| Abstract |
|---|
|
|
|---|
B (NF
B), an hypoxia-dependent transmission factor, could reduce this expression. Methods: Human umbilical vein endothelial cells were cultured and exposed to normoxia and hypoxia in the presence of lipopolysaccharide (LPS). The endothelial cells were thereafter treated with salicylate or indomethacin under the same conditions. The surface expression of ICAM-1 was measured by whole cell enzyme-linked immunosorbent assay (ELISA) and the NF
B expression by Western blotting. Results: In the presence of LPS and under hypoxic conditions, the endothelial cells produced a 300±41% increased expression of ICAM-1 compared with normoxia. The addition of salicylate (0.0220 mM) completely inhibited the enhanced expression of ICAM-1, the addition of indomethacin at equivalent concentrations did not reduce ICAM-1 expression under either condition. Conclusion: ICAM-1 expression is greatly enhanced by the hypoxic endothelial cell in the presence of circulating endotoxin. Pre-treatment with salicylate completely abolishes the enhanced expression. The study suggests that salicylate administered before cardiopulmonary bypass might protect the heart against ischemic/reperfusion injuries and reduce the load of the overall inflammatory reaction.
Key Words: Endothelium Ischemia/reperfusion injury Treatment
| Introduction |
|---|
|
|
|---|
Migration of leukocytes across the intact endothelium occurs through a concerted series of adhesion and de-adhesion events involving a number of cell surface adhesion proteins
[4]. Previous studies have demonstrated that short-term hypoxia or anoxia induces increased adhesion of leukocytes to vascular endothelial cells mediated by the upregulation of endothelial adhesion molecules
[5]
[6]. Intercellular adhesion molecule-1 (ICAM-1, CD54) mediates the firm adherence of leukocytes to the endothelium
[4]. ICAM-1 expression is readily induced by stimulation of cell surface receptors by a number of inflammatory mediators, including lipopolysaccharides (LPS) and cytokines
[4]. In addition, ICAM-1 is regulated by the transcription factor NF-
B (nuclear factor-
B)
[7] which has been shown in previous studies to be regulated by hypoxia
[8].
A strategy that would inhibit the migration of leukocytes across the endothelial layer would blunt the inflammatory response induced by cardio-pulmonary bypass and prevent, or at least reduce, the tissue ischemia-reperfusion injuries
[9]. Because salicylate is inhibiting NF-
B, the authors hypothesized that the administration of this drug would reduce the enhancement of ICAM-1 expression. To test the hypothesis, the authors used an in-vitro model of endothelial cell and the authors were simulating the CPB.
| Material and methods |
|---|
|
|
|---|
B.
Cell culture
Human umbilical vein endothelial cells (HUVEC) were obtained and harvested using 0.1% collagenase (Worthington Biochemical, Freehold, NJ). Endothelial monolayers were established, maintained and subcultured with DMEM (Gibco, Grand Island, NY) containing 10% heat inactivated fetal calf serum, glucose, pyruvate, glutamine, penicillin and streptomycin. Confluent endothelial monolayers exhibited typical cobblestone appearance and expressed characteristics of endothelial cells like the uptake of acetylated low density lipoproteins (Biomedical Technology, Stoughton, MA). Endothelial cell passages 25 were used for experiments.
Creation of hypoxic conditions
Confluent endothelial monolayers were exposed to hypoxia as follows, growth medium was replaced with fresh media equilibrated with hypoxic gas mixture and cells were placed in the hypoxic chamber (Coy Laboratory Products, Ann Arbor, MI). This hypoxia chamber consists of an airtight glove box with the atmosphere continuously monitored by an oxygen analyzer interfaced with oxygen and nitrogen flow adaptors. Oxygen concentrations were adjusted by oxygen and nitrogen flow adaptors and were obtained by the balance between nitrogen, carbon dioxide (ambient 5% CO2) and water vapor from the humidified chamber. Media pO2 and pH were measured in a Ciba-Corning 238 Blood Gas Analyzer (Chiron Diagnostics, Norwood, MA).
Cell surface immunoassay
ICAM-1 cell surface expression was quantified using a cell surface enzyme-linked immunosorbent assay (ELISA). Endothelial cells were grown and assayed for antibody binding following exposure to normoxia or hypoxia in the presence of LPS. Endothelia were lightly fixed with paraformaldehyde (1% w/v in phosphate buffered saline) to preserve cell surface protein. Cells were washed with HBSS (Sigma, St. Louis, MO), blocked with media for 30 min at 4°C. Anti-ICAM-1 mAb (clone P2A4 obtained from the Developmental Studies Hybridoma Bank, Iowa City IA, used as undiluted cell culture supernatant) was added to fixed cells and allowed them to incubate for 2 h at 4°C. Where indicated, mAb to MHC class I (clone W6/32 obtained from the American Type Culture Collection, used as 1:100 diluted ascitic fluid) was used as control. After washing with HBSS, a peroxidase conjugated sheep anti-mouse secondary antibody (Cappel, West Chester, PA) was added. After washing plates were developed by addition of peroxidase substrate (2,2'-azino bis(3-ethylbenzthiazoline-6-sulfonic acid), 1 mM final concentration, Sigma) and read on a microtiter plate spectrophotometer at 405 nm (Molecular Devices). Controls consisted of media only and secondary antibody only.
NF
B Western blotting
HUVEC were grown to confluence on six well plates and exposed to experimental conditions, washed, lysed and debris was removed as described above. Proteins were measured (DC protein assay, BioRad, Hecules, CA). Samples (50 µg/lane) of HUVEC lysates were separated by non-reducing SDS PAGE, transferred to nitrocellulose and blocked overnight in blocking buffer (250 mM NaCl, 0.02% Tween-20, 5% goat serum and 3% bovine serum albumin). Primary Ab (rabbit polyclonal specific for p65 subunit of NF
B, Biomol Research Labs, Plymouth Meeting, PA) was added for 3 h, blots were washed and species-matched peroxidase-conjugated secondary Ab was added. Labeled bands from washed blots were detected by ECL. Resulting 65 kD NF
B bands were quantified from scanned images using NIH Image software (Bethesda, MD). Such 65 kD band were specific for NF
B since preincubation of rabbit polyclonal antibody with standard p65 antigen (provided by Biomol as a control) resulted in a diminution of the 65 kD band by more than 70%.
Data presentation
ELISA data were compared by one or two-factor analyze of variance (ANOVA) or by students t-test. Values are expressed as the mean and S.E.M. of n experiments.
| Results |
|---|
|
|
|---|
Sodium salicylate normalizes hypoxia-elicited ICAM-1 surface expression
The authors first examined the induction of ICAM-1 surface expression induced by LPS with endothelial exposure to hypoxia and normoxia. Under hypoxic conditions a 2-fold increase in ICAM-1 expression was observable on HUVEC (two-way ANOVA, P<0.025 compared with normoxia) (
Fig. 1
Fig. 2
). As shown in
Fig. 1, salicylate (NaSal, concentration range 0.0220 mM) dose dependently decreased LPS-stimulated ICAM-1 on HUVEC under conditions of both hypoxia (one-way ANOVA, P<0.01) and normoxia (one-way ANOVA, P<0.05). Endothelial exposure to indomethacin (concentration range 0.0220 mM) at equivalent concentrations did not influence ICAM-1 expression under either condition (
Fig. 2, P=not significant for both). In comparison sodium salicylate but not indomethacin is inhibiting the expression of LPS stimulated HUVEC of ICAM-1 under hypoxic conditions.
|
|
B. Increased periods of hypoxia alone resulted in a graded increase in p65 content over normoxic controls (
Fig. 3
). The concentrations of NaSal (2 and 20mM) determined to be effective for decreasing ICAM-1 expression also resulted in decreased endothelial NF
B under conditions of both normoxia and hypoxia (
Fig. 3).
|
| Discussion |
|---|
|
|
|---|
There are different ways to protect the leukocyte-endothelial interactions of the ischemia-reperfusion injury. Therapeutical interventions can be categorized as those targeted at inactivating the triggers of the response and those targeted at inactivating the effectors of the response. The former category primarily encompasses drugs or devices designed to reduce cytokine and endotoxin release such as heparin-coated extracorporal circuits or glucocorticoids
[16]
[17]
[18]
[19]
[20]. The second category of interventions includes drugs or devices to attenuate the effects of adhesion molecules. As the authors have shown in the result part under the condition of hypoxia NF
B was increased. The addition of sodium salicylate, but not indomethacin, diminished augmentation of both ICAM-1 expression and cellular content of NF
B. Such observations are consistent with a previous report indicating that sodium salicylate can inhibit induction through NF
B
[28]. A contribution of cyclooygenase in this context could be excluded by the addition of indomethcin which had no effect to the expression of ICAM-1 under hypoxic conditions. The adhesion molecules, whether expressed on leukocytes or endothelial cells can be blocked by monoclonal antibodies. This approach has been examined in various animal models of myocardial ischemia, including a surgically relevant preparation of heterotopic rabbit heart transplantation and an isolated blood-perfused swine-heart model subjected to 6 h of cold cardioplegic ischemia
[21]
[22]. None of these genetically engineered compounds is clinically available yet. Alternative therapies that can interfere with adhesion molecules and have been approved for human use are being considered. Both glucocorticoid and adenosine-regulating agent acadesine have been shown to decrease CD11b/CD18 upregulation in patients undergoing open-heart procedures
[23]
[24]. Furthermore, low-dose aprotinin has been reported to have a similar anti-inflammatory effect to that of methylprednisolon in decreasing the bypass-induced release of TNF-
and neutrophil CD 11b upregulation
[25]. A possible more effective approach for limiting the effects of neutrophil interactions to vascular endothelium might be the elimination of themselves by sequestering them into appropriate filters. A recent Japanese study has shown that leukocyte and platelet depletion with a blood cell separator reduces postoperative respiratory dysfunction
[26]. At the institution the efficiency of such a device was tested and leukocyte filtration failed to improve postoperative lung function
[27].
The results suggest that the addition of salicylate to the cardio-pulmonary bypass model completely inhibited the enhanced expression of ICAM-1 by blocking the hypoxia dependent NF
B transmission factor, the addition of indomethacin at equivalent concentrations did not influence ICAM-1 expression under either condition. Thus, this study suggests that salicylate administered before cardiopulmonary bypass might protect the heart against ischemic/reperfusion injuries and reduce the load of the overall inflammatory reaction.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
: An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 1992;90:2333-2339.
B and cytokine-inducible enhancers. FASEB J 1995;9:899-909.[Abstract]
m Holen E, Tangen G, Abdeonoor M, Ringdal MAL, Øystese R, Venge P Complete heparin-coated cardiopulmonary bypass and low heparin dose reduce complement and granulocyte activation. Eur J Cardiothorac Surg 1996;10:54-60.[Abstract]
B by sodium salicylate and aspirin. Science 1994;265:956-959.This article has been cited by other articles:
![]() |
M Buyukates, S Acikgoz, O Kandemir, E Aktunc, E Ceylan, and M Can Use of warm priming solution in open heart surgery: its effects on hemodynamics and acute inflammation Perfusion, March 1, 2008; 23(2): 89 - 94. [Abstract] [PDF] |
||||
![]() |
U. P. Schurr, G. Zund, S. P. Hoerstrup, J. Grunenfelder, F. E. Maly, P. R. Vogt, and M. I. Turina Preoperative administration of steroids: influence on adhesion molecules and cytokines after cardiopulmonary bypass Ann. Thorac. Surg., October 1, 2001; 72(4): 1316 - 1320. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Selzman, S. A. Miller, and A. H. Harken Therapeutic implications of inflammation in atherosclerotic cardiovascular disease Ann. Thorac. Surg., June 1, 2001; 71(6): 2066 - 2074. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Labarrere, D. R. Nelson, S. J. Miller, J. M. Nieto, J. A. Conner, D. E. Pitts, P. C. Kirlin, and H. G. Halbrook Value of Serum-Soluble Intercellular Adhesion Molecule-1 for the Noninvasive Risk Assessment of Transplant Coronary Artery Disease, Posttransplant Ischemic Events, and Cardiac Graft Failure Circulation, September 26, 2000; 102(13): 1549 - 1555. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Grunenfelder, G. Zund, A. Schoeberlein, E.R. Schmid, U. Schurr, R. Frisullo, F. Maly, and M. Turina Expression of adhesion molecules and cytokines after coronary artery bypass grafting during normothermic and hypothermic cardiac arrest Eur. J. Cardiothorac. Surg., June 1, 2000; 17(6): 723 - 728. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Grunenfelder, G. Zund, A. Schoeberlein, F. E. Maly, U. Schurr, S. Guntli, K. Fischer, and M. Turina Modified ultrafiltration lowers adhesion molecule and cytokine levels after cardiopulmonary bypass without clinical relevance in adults Eur. J. Cardiothorac. Surg., January 1, 2000; 17(1): 77 - 83. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Stefanec Circulating Apoptotic Endothelial Cells Blood, August 15, 1999; 94(4): 1482 - 1483. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |